Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. KVUE
stocks logo

KVUE

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
3.70B
+1.17%
0.228
-12.48%
3.87B
+3.39%
0.258
+7.7%
3.95B
+2.96%
0.303
+4.63%
Estimates Revision
The market is revising Downward the revenue expectations for Kenvue Inc. (KVUE) for FY2025, with the revenue forecasts being adjusted by -0.63% over the past three months. During the same period, the stock price has changed by -17.28%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.63%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-0.15%
In Past 3 Month
Stock Price
Go Down
down Image
-17.28%
In Past 3 Month
Wall Street analysts forecast KVUE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KVUE is 19.42 USD with a low forecast of 17.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
Wall Street analysts forecast KVUE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KVUE is 19.42 USD with a low forecast of 17.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
9 Hold
0 Sell
Moderate Buy
Current: 16.990
sliders
Low
17.00
Averages
19.42
High
23.00
Current: 16.990
sliders
Low
17.00
Averages
19.42
High
23.00
Argus
John Staszak
Hold
to
Buy
upgrade
$120
2025-11-13
Reason
Argus
John Staszak
Price Target
$120
2025-11-13
upgrade
Hold
to
Buy
Reason
As previously reported, Argus analyst John Staszak upgraded Kimberly-Clark (KMB) to Buy from Hold with a $120 price target. The firm notes that the stock has underperformed recently, but the company has delivered a Q3 earnings beat and also announced the acquisition of Kenvue (KVUE) that is expected to close in the second half of next year, the analyst tells investors in a research note.
Barclays
Equal Weight
maintain
$17 -> $18
2025-11-10
Reason
Barclays
Price Target
$17 -> $18
2025-11-10
maintain
Equal Weight
Reason
Barclays raised the firm's price target on Kenvue to $18 from $17 and keeps an Equal Weight rating on the shares following the Q3 report. The company's sales came in below expectations, with low incidence levels and continued destocking, the analyst tells investors in a research note. However, the firm sees "some green shoots" in Kenvue's Skin Health and Beauty segment.
Morgan Stanley
Equal Weight
downgrade
$144 -> $125
2025-11-04
Reason
Morgan Stanley
Price Target
$144 -> $125
2025-11-04
downgrade
Equal Weight
Reason
Morgan Stanley lowered the firm's price target on Kimberly-Clark (KMB) to $125 from $144 and keeps an Equal Weight rating on the shares after the company announced an agreement to acquire Kenvue (KVUE). The firm understands the pullback in shares given a large degree of execution risk with the deal and uncertainty on Kenvue's portfolio, and the analyst is lowering the firm's target to reflect higher risk from the deal and execution uncertainty, though it sees "the glass as more half full" on Kimberly-Clark's stock after the pullback, the analyst tells investors.
Wells Fargo
Equal Weight
downgrade
$129 -> $110
2025-11-04
Reason
Wells Fargo
Price Target
$129 -> $110
2025-11-04
downgrade
Equal Weight
Reason
Wells Fargo lowered the firm's price target on Kimberly-Clark to (KMB) $110 from $129 and keeps an Equal Weight rating on the shares. The firm notes the company intends to acquire Kenvue (KVUE) in a stock and cash deal valued at $48.7B. Kimberly-Clark's stock reaction was historically negative, reflecting a material change in the investment case, risks associated with Kenvue, and needed execution on big synergy targets.
Canaccord
Buy
to
Hold
downgrade
$26 -> $15
2025-10-29
Reason
Canaccord
Price Target
$26 -> $15
2025-10-29
downgrade
Buy
to
Hold
Reason
Canaccord downgraded Kenvue to Hold from Buy with a price target of $15, down from $26.
Canaccord
Buy
to
Hold
downgrade
$26 -> $15
2025-10-29
Reason
Canaccord
Price Target
$26 -> $15
2025-10-29
downgrade
Buy
to
Hold
Reason
As previously reported, Canaccord downgraded Kenvue to Hold from Buy with a price target of $15, down from $26. With the HHS looking to link acetaminophen use in pregnancy to autism, Texas suing the company for deceptive marketing and lawsuits in the UK bringing talc liability to the table, the firm believes continued negative headlines and legal issues hamper the company's turnaround and also likely hamper any potential sale of all or part of the company. Finding itself in the news, for reasons "it can't generally control," will likely keep a lid on valuation, the analyst argues.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Kenvue Inc (KVUE.N) is 15.68, compared to its 5-year average forward P/E of 18.21. For a more detailed relative valuation and DCF analysis to assess Kenvue Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
18.21
Current PE
15.68
Overvalued PE
20.30
Undervalued PE
16.13

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
12.84
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
13.92
Undervalued EV/EBITDA
11.77

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2.59
Current PS
0.00
Overvalued PS
2.89
Undervalued PS
2.28
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

KVUE News & Events

Events Timeline

(ET)
2025-11-14
16:09:37
Kenvue Inc Experiences Mixed Sentiment as Shares Decline by 0.57%
select
2025-11-13 (ET)
2025-11-13
16:09:42
Kenvue Inc Experiences Mixed Sentiment as Shares Rise 0.69%
select
2025-11-12 (ET)
2025-11-12
11:35:39
Kenvue Inc Experiences Moderate Bullish Momentum as Shares Rise 2.86%
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
00:22 AMGlobenewswire
Repare Therapeutics to Receive $1.82 per Share in Sale to XenoTherapeutics
  • Shareholder Returns: Repare Therapeutics Inc. is set to receive $1.82 per share in cash from its sale to XenoTherapeutics, which is expected to provide substantial cash returns to shareholders, thereby enhancing shareholder confidence.
  • Merger Transaction: The deal will also grant Repare shareholders a non-transferable contingent value right that entitles them to additional cash payments under certain conditions, further increasing potential shareholder gains.
  • Market Reaction: As the transaction progresses, the market has shown a positive response to Repare's stock performance, indicating investor approval of the deal, which may influence future investment decisions.
  • Legal Support: Monteverde & Associates PC, acting as the representing law firm, has recovered millions for shareholders, demonstrating its strong capabilities and reputation in securities class action litigation.
[object Object]
Preview
7.0
12-02Newsfilter
Shein Under Investigation by Texas AG for Labor and Safety Violations
  • Legal Investigation Escalation: Texas Attorney General Ken Paxton announced an investigation into Shein, focusing on potential violations of state laws regarding unethical labor practices and the sale of unsafe consumer products, which could lead to legal liabilities and reputational damage for the company.
  • Product Safety Concerns: The probe will examine whether Shein used toxic or hazardous materials or misled consumers about product safety and ethical sourcing, potentially undermining consumer trust and negatively impacting sales.
  • Increased International Pressure: Following the discovery of childlike sex dolls and illegal weapons for sale on Shein's platform by France's consumer fraud agency, the French government is seeking to suspend the company's operations in the country, intensifying compliance pressures on Shein in international markets.
  • Data Privacy Scrutiny: Paxton indicated that the investigation will also focus on Shein's data collection and privacy practices, which could affect its operational strategies and consumer relationships in the U.S. market.
[object Object]
Preview
9.5
11-25CNBC
Morning Squawk: Retail Earnings, Emerging AI Leaders, Amazon's $50 Billion Investment, and More

  • Retail Earnings Reports: Major retail companies have reported earnings, providing insights into consumer behavior ahead of Black Friday, following a series of retail earnings last week.

  • AI Investment Surge: Amazon announced a $50 billion investment to enhance its AI and high-performance computing capabilities for U.S. government clients, while the AI sector saw a resurgence with Broadcom and Alphabet leading the market.

  • Legal Rulings: A U.S. District Judge dismissed criminal cases against former FBI Director James Comey and New York Attorney General Letitia James due to issues with the appointment of the interim U.S. attorney, marking a setback for President Trump.

  • NHL Franchise Valuations: The average NHL team value increased by 15% to $2.2 billion, with the Toronto Maple Leafs valued at $4.3 billion, driven by rising media rights deals.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Kenvue Inc (KVUE) stock price today?

The current price of KVUE is 16.99 USD — it has increased 0.12 % in the last trading day.

arrow icon

What is Kenvue Inc (KVUE)'s business?

Kenvue Inc. is a consumer health company. The Company’s differentiated portfolio of brands includes Tylenol, Neutrogena, Listerine, Johnson’s, BAND-AID, Aveeno, Zyrtec, and Nicorette. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include pain care; cough, cold, and allergy; digestive health; smoking cessation; eye care; and other products. Self Care segments include brands such as Tylenol, Motrin, Nicorette, Benadryl, Zyrtec, Zarbee’s, ORSLTM, Rhinocort, and Calpol. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women’s health, wound care, and other products. Its portfolio includes Self Care, Skin Health and Beauty, and Essential Health products which connect with consumers across North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM).

arrow icon

What is the price predicton of KVUE Stock?

Wall Street analysts forecast KVUE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KVUE is 19.42 USD with a low forecast of 17.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Kenvue Inc (KVUE)'s revenue for the last quarter?

Kenvue Inc revenue for the last quarter amounts to 3.76B USD, decreased -3.46 % YoY.

arrow icon

What is Kenvue Inc (KVUE)'s earnings per share (EPS) for the last quarter?

Kenvue Inc. EPS for the last quarter amounts to 0.21 USD, increased 5.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Kenvue Inc (KVUE)'s fundamentals?

The market is revising Downward the revenue expectations for Kenvue Inc. (KVUE) for FY2025, with the revenue forecasts being adjusted by -0.63% over the past three months. During the same period, the stock price has changed by -17.28%.
arrow icon

How many employees does Kenvue Inc (KVUE). have?

Kenvue Inc (KVUE) has 22000 emplpoyees as of December 05 2025.

arrow icon

What is Kenvue Inc (KVUE) market cap?

Today KVUE has the market capitalization of 32.55B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free